Does sermorelin increase testosterone in men?

No. Sermorelin signals the growth-hormone pathway and does not raise testosterone. In the 1997 Khorram trial, testosterone, dihydrotestosterone and sex hormone-binding globulin were unchanged even while GH and IGF-1 increased. Suspected testosterone deficiency is a separate diagnosis based on compatible symptoms and consistently low testosterone measurements, not an IGF-1 result or a response to sermorelin.

What did sermorelin studies find in older men?

The findings were mixed and came from small studies. Fourteen days of GHRH(1–29) raised GH and IGF-1 in 10 older men. A six-week study of 11 men raised nocturnal GH but not IGF-1 and found no DEXA body-composition change. A separate trial reported about 1 kg more lean mass in nine men after a modified analogue, without lower fat mass.

Can sermorelin help men build muscle?

A dependable muscle-building effect has not been established. One small mixed-sex trial reported about 1 kg more lean mass in its nine male participants, while another study of 11 older men found no change in DEXA measures of muscle or fat after six weeks. These results do not establish how much muscle an individual man might gain or whether a change would improve function.

Does sermorelin improve sleep or workout recovery?

Reliable benefits for either outcome have not been shown. A small mixed-sex study of intravenous GHRH reported fewer awakenings, but it did not test prescribed subcutaneous sermorelin, and another GHRH(1–29) analogue trial found no improvement in reported sleep quality. The older-men studies did not measure soreness, injury healing, recovery time or return to sport after training.

How is sermorelin different from TRT?

They target different hormone systems. Sermorelin asks the pituitary to release growth hormone and may change IGF-1. Testosterone replacement supplies testosterone for clinically diagnosed hypogonadism. One does not substitute for the other, and fatigue, reduced strength, low libido or poor sleep cannot identify which pathway is involved without a medical history and appropriate testing.

Is compounded sermorelin an approved product for men?

No. No FDA-approved sermorelin product is currently marketed; the compounded formulation offered here is not FDA-approved. Geref was historically approved for pediatric growth-hormone deficiency and diagnostic testing, but its approvals were withdrawn in 2009 at the applicant's request. FDA later determined that the withdrawal was not for safety or effectiveness reasons. A prescriber evaluates compounded treatment separately for the individual patient.

Sermorelin for Men: Testosterone, Muscle & Sleep

Sermorelin for men is best understood as a growth-hormone question, not a testosterone treatment. It signals the pituitary to release growth hormone, which may raise the downstream marker IGF-1 when that pathway responds. Small studies in older men found clear hormone changes but inconsistent results for lean mass and strength. They did not show that sermorelin raises testosterone, reliably improves sleep, or speeds recovery after exercise. Those limits matter because fatigue, reduced strength, poor sleep and low libido can have causes that sermorelin does not address.

What sermorelin for men actually targets

Sermorelin is the 29-amino-acid active fragment of growth-hormone-releasing hormone, or GHRH. Instead of supplying growth hormone directly, it asks a responsive pituitary to release the body's own hormone in pulses. IGF-1, produced largely in the liver in response to GH, is a steadier downstream marker than a random GH measurement.

GH output changes with age, but age alone is not a diagnosis. In the Corpas trial in JCEM in 1992, 10 healthy men with a mean age of 68 had lower IGF-1 and shorter spontaneous GH peaks than nine men with a mean age of 26. Fourteen days of GHRH(1–29) raised GH measures and IGF-1 at the higher study dose. The trial measured a biochemical response; it did not establish a change in muscle, fat, sleep or day-to-day function.

That is the central distinction throughout the evidence. A higher GH peak or IGF-1 result shows that the axis responded. It does not, by itself, prove that a man will feel or perform differently. The broader sermorelin benefits evidence should be read with that sequence in mind.

What the older-men studies found

The adult evidence comes from small studies with different schedules and endpoints. Their findings should not be blended into one promise.

Study	Men and duration	Hormone finding	Practical finding
Corpas, JCEM 1992	10 older men; 14 days	GH measures and IGF-1 rose at the higher study dose	Body composition and sleep were not outcomes
Vittone, Metabolism 1997	11 men ages 64–76; 6 weeks	Nocturnal GH rose, but IGF-1 did not	No change in weight, BMI, waist-to-hip ratio, or DEXA muscle and fat; 2 of 6 strength measures and one endurance test improved
Khorram, JCEM 1997	9 men within a 19-person trial; 4 months after placebo lead-in	Nocturnal GH and IGF-1 rose with a modified GHRH(1–29) analogue	Men gained about 1 kg of lean mass; fat mass, testosterone and reported sleep quality did not change

The Vittone study is especially useful for expectations. Two upper-body strength measures and an abdominal-crunch endurance test improved, but most strength measures did not, and the scans showed no muscle or fat change. There was no untreated parallel group, and 11 participants is too small to predict an individual result.

The Khorram study provides the modest lean-mass signal. It used a modified GHRH(1–29) analogue rather than proving an outcome for every compounded sermorelin formulation. It also found no reduction in fat mass. The site's separate sermorelin evidence verdict puts these biochemical and clinical findings in a broader context.

CJC-1295 with ipamorelin is a separate secretagogue strategy, not a stronger version of the same evidence. It combines GHRH-receptor and ghrelin-receptor signaling, and no head-to-head male trial shows that it improves outcomes that sermorelin did not. The CJC-1295 and ipamorelin overview explains why that combination requires its own clinical rationale.

Sermorelin and testosterone are different therapies

Sermorelin does not raise testosterone. In the Khorram study, testosterone, dihydrotestosterone and sex hormone-binding globulin were unchanged even though GH and IGF-1 rose. The two endocrine pathways also start with different signals: sermorelin acts on pituitary somatotroph cells in the GH–IGF-1 axis, while testosterone production is governed mainly by hypothalamic GnRH and pituitary LH in the reproductive axis.

Testosterone replacement therapy supplies testosterone for diagnosed hypogonadism. The Endocrine Society guideline recommends making that diagnosis only when compatible symptoms occur with unequivocally and consistently low testosterone, confirmed with repeat morning testing. Sermorelin cannot substitute for that evaluation, and a low-testosterone question should not be inferred from an IGF-1 result.

The reverse is also true: TRT and sermorelin are not interchangeable ways to pursue the same lab number. A clinician choosing between them is first deciding which axis, if either, plausibly explains the problem.

Sleep and workout recovery need cautious expectations

GH secretion and sleep are connected. Much of the largest daily GH pulse occurs around sleep onset, while aging is associated with less slow-wave sleep and lower nocturnal GH output. That relationship makes a sleep claim sound intuitive, but the intervention data are mixed.

A 1997 study in Neurobiology of Aging gave intravenous GHRH or placebo to 13 older adults, including eight men. It reported fewer awakenings and a longer first non-REM period, but the response was smaller than in younger adults and the intervention was not prescribed subcutaneous sermorelin. Khorram found no improvement in reported sleep quality. The evidence therefore does not support treating insomnia or sleep apnea with sermorelin.

Workout recovery is even less directly studied. The older-men trials measured selected strength, endurance or body-composition outcomes; they did not measure recovery time after training, injury healing, soreness or return to sport. A man who feels persistently unrested still needs common causes considered, including sleep apnea, thyroid disease, anemia, medication effects and training load.

How a provider frames the decision

A useful evaluation starts with the symptom and a measurable goal, not with an assumption that age-related GH decline needs correction. A provider may consider age-adjusted IGF-1, pituitary history, thyroid and glucose status, medications, cancer history, sleep symptoms and whether the intended outcome was actually studied. A single random GH value is difficult to interpret because secretion is pulsatile. Tolerability and screening questions are covered in sermorelin side effects.

As of September 2026, no FDA-approved sermorelin product is currently marketed; the compounded formulation offered here is not FDA-approved. FDA records show that Geref's approvals were withdrawn effective June 18, 2009, at the applicant's request, and the agency later determined that the withdrawal was not for safety or effectiveness reasons. A licensed provider may still prescribe a compounded formulation when appropriate; that decision is between the patient and the doctor.

The useful outcome is a defined one

A sound plan separates a lab response from a meaningful clinical response. Before treatment, the provider and patient can define what is being evaluated and how it will be measured. That might include an age-adjusted lab marker alongside a specific functional concern, while recognizing that the small older-men trials do not provide a dependable timetable or guarantee.

At Promise, a licensed provider reviews every request and prescribes or declines based on medical eligibility; not everyone qualifies. That review is particularly important when common symptoms overlap across sleep, thyroid, metabolic, pituitary and testosterone-related conditions.